Biota Pharmaceuticals to Present at the 2015 BIO CEO & Investor Conference
February 03 2015 - 03:00PM
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a
biopharmaceutical company focused on the discovery and development
of products to prevent and treat serious and potentially
life-threatening viral respiratory infectious diseases, announced
today that Biota CEO & President Joseph Patti will present a
corporate overview at the 2015 BIO CEO & Investor Conference.
The presentation will take place on Tuesday, February 10, 2015 at
3:00 p.m. EST at the Waldorf Astoria Hotel in New York, NY.
A live webcast of the presentation can be accessed under "Events
and Presentations" in the Investors section of the Company's
website at www.biotapharma.com or at
http://www.veracast.com/webcasts/bio/ceoinvestor2015/91221174867.cfm.
A replay of the webcast will be archived for 30 days following the
presentation.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals, Inc. is a company focused on the
discovery and development of products to treat serious viral
respiratory infectious diseases. The Company currently has two
clinical-stage Phase 2 product candidates: (i) laninamivir
octanoate, which is being developed as a one-time treatment for
influenza A and B infections; and (ii) vapendavir, a potent, broad
spectrum capsid inhibitor of enteroviruses in development for the
treatment of human rhinovirus infected patients with underlying
respiratory illnesses, such as moderate-to-severe asthma and
chronic obstructive pulmonary disease (COPD). The Company is also
conducting IND-enabling studies with BTA-C585, an orally
bioavailable F protein inhibitor, in development for the treatment
of respiratory syncytial virus infections. For additional
information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer
(678) 221-3351
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(267) 909-9237
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2023 to Mar 2024